Acetyl Cysteine for the Treatment of Obsessive Compulsive Disorder (OCD): A Double-Blind, Randomised, Placebo-Controlled Clinical Trial

Phase 2

Completed

• Conditions: Mental Health - Anxiety; Obsessive Compulsive Disorder (OCD)

• Registration Number: ACTRN12613000310763
• Lead Sponsor: The Melbourne Clinic

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2013-03-20
• Last Update Posted: 13 January 2020

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 80

Inclusion Criteria

Fulfil DSM-IV TR diagnostic criteria for OCD
Self reported OCD will require a diagnosis from a physician
Score 16+ on the Y-BOCS at the time of recruitment
No other treatment, or be on stable treatment i.e. minimum 4 weeks of treatment or minimum of 12 weeks if a new treatment (e.g. SSRI, CBT)
Female participants of child bearing age or sexually active are required to be using effective contraception

Exclusion Criteria

Known or suspected serious medical disorder i.e. cancer, organ failure
Patients undergoing current psychological programs for their OCD (a four week wash out period will be required for eligibility)
Bipolar I, schizophrenia, epilepsy
Gastrointestinal ulcers
Pregnancy or breastfeeding
History of hypersensitivity or intolerance to NAC
Patients taking 100 micrograms of selenium or 500 IU of vitamin E

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Severity in symptoms will be measured with the Yale-Brown Obsessive Compulsive Scale (Y-BOCS)[Reviewed at baseline, week 4, 8, 12 and 16]

Secondary Outcome Measures

Name	Time	Method
nil[nil]